Zynerba Pharmaceuticals Announces New Date for Reconvened Annual Meeting

Zynerba Pharmaceuticals

DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) announced that the new date for the adjourned 2023 Annual Meeting of Stockholders is August 11, 2023, at 9:00 a.m. EDT in order to provide stockholders additional time to consider and vote on Proposal 2 to amend the Sixth Amended and Restated Certificate of Incorporation of the Company to effect a reverse stock split of the Company’s outstanding shares of common stock by a ratio of any whole number between 1-for-2 and 1-for-50, at any time prior to November 1, 2023, the implementation and timing of which shall be subject to the discretion of the Board of Directors of the Company. The August 11, 2023 meeting date replaces the previously announced July 27, 2023 date for the reconvened meeting and will be a “virtual” meeting of stockholders. The record date for the adjourned Annual Meeting continues to be April 17, 2023.

A stockholder may use one of the following simple methods to vote:

  • Vote by Internet at www.voteproxy.com until 11:59 PM EDT on August 10, 2023, using the control number appearing on the proxy card.
  • Vote by telephone by calling the toll-free telephone number 1-800-776-9437 until 11:59 PM EDT on August 10, 2023, using their control number appearing on the proxy card.
  • Vote by mail by marking, dating and signing the proxy card, and returning it in the postage-paid envelope provided to American Stock Transfer & Trust Company, LLC.
  • Vote at the virtual Annual Meeting by joining the meeting at https://web.lumiagm.com/236626312 (password: zyne2023) using the control number included on the proxy card.
READ:  Neuronetics to Present at William Blair Growth Conference

Proxies previously submitted with respect to Proposal 2 will be voted at the reconvened Annual Meeting unless properly revoked; stockholders who have previously submitted their proxy or otherwise voted with respect to Proposal 2 and who do not want to change their vote need not take any action.

Details of the reverse stock split are included in the Company’s Proxy Statement for the Annual Meeting. The primary objective of implementing a reverse split is to satisfy the minimum bid price requirement for continued listing on the Nasdaq Capital Market. The Company’s Board believes that effecting the reverse split would increase the price of our common stock which would, among other things, help the Company to meet certain continued listing requirements of the Nasdaq Capital Market, appeal to a broader range of investors to generate interest in the Company, and improve perception of the Company’s common stock as an investment security.

If stockholders have any questions or need assistance with processing their vote, please contact the Company’s proxy solicitor, MacKenzie Partners, Inc. (email: proxy@mackenziepartners.com, or toll-free: 1-800-322-2885).

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and Microsoft Start.